A deep dive into the cellular biology behind exosome therapy — and why the evidence is genuinely compelling
Science & Wellness Feature | Reviewed by our Medical Editorial Board | 2025Reading time: approximately 20 minutes
In the world of regenerative medicine, few developments have generated as much genuine scientific interest — and as much popular excitement — as exosome therapy. These microscopic biological particles, invisible to the naked eye and measured in billionths of a metre, represent one of the most significant leaps forward in our understanding of how cells communicate, repair, and renew themselves. And in the specific context of hair restoration, the evidence for their effectiveness is growing at a pace that has surprised even the researchers conducting the studies.
This is not hype. The clinical literature on exosome therapy for hair loss, while still maturing, is already substantive enough to draw clear and meaningful conclusions. The mechanisms are understood. The safety profile is well-established. And at clinics like Mesglo Regenerative Aesthetic Clinic in Marylebone, London, practitioners with genuine expertise — including lead clinician Rahena, whose hands-on experience with exosome treatments is backed by advanced specialist certification — are delivering results that are transforming the lives of patients who had all but given up hope of significant improvement.
This feature sets out to do something rare in the beauty and wellness space: to explain the science properly, without oversimplification and without exaggeration. We will explore what exosomes are, how they act upon hair follicles, what the peer-reviewed research demonstrates, and why the combination of rigorous science and expert clinical application makes this one of the most compelling stories in contemporary aesthetic medicine.
"Exosome therapy is not a trend. It is the product of decades of fundamental research in cell biology, now reaching clinical maturity. The hair restoration applications we are seeing today are just the beginning."
What Are Exosomes? A Cell Biology Primer
To understand why exosome therapy works for hair loss, it is necessary to first understand what exosomes are — and why they represent such a profound development in biomedical science.
Extracellular Vesicles and the Language of Cells
For much of the 20th century, scientists believed that cells communicated primarily through direct contact or through soluble signalling molecules (such as hormones and cytokines) that diffused through tissue. The discovery and characterisation of extracellular vesicles — tiny membrane-bound particles released by virtually all cell types — upended this understanding entirely.
Exosomes are a specific subclass of extracellular vesicles, typically ranging from 30 to 150 nanometres in diameter (for context, the average human hair is approximately 70,000 nanometres wide). They are formed within cells through a process of endosomal membrane invagination, and are released into the extracellular space — and ultimately into the bloodstream and lymphatic system — where they can travel to distant sites and deliver their cargo to target cells. The National Institutes of Health (NIH) has published extensive research recognising exosomes as key mediators of intercellular communication with significant therapeutic potential across multiple disease areas.
The Cargo That Makes the Difference
The reason exosomes are so scientifically fascinating — and so therapeutically powerful — lies in what they carry. Each exosome contains:
- MicroRNAs (miRNAs): Small non-coding RNA molecules that regulate gene expression in recipient cells, influencing which proteins are produced and at what levels
- Messenger RNA (mRNA): Templates for direct protein synthesis in target cells
- Growth factors: Including vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), platelet-derived growth factor (PDGF), and insulin-like growth factor 1 (IGF-1) — all of which have documented roles in follicular biology
- Proteins and enzymes: Including heat shock proteins, integrins, and signalling molecules that regulate cellular behaviour
- Lipids: Including sphingomyelins and cholesterol, which constitute the vesicle membrane and participate in cellular signalling
When an exosome fuses with a target cell — through endocytosis or direct membrane fusion — it delivers this cargo directly into the cell, with immediate effects on cellular behaviour. In the context of hair follicles, these effects are precisely what is needed to address the key drivers of thinning and loss.
???? Scientific ReferenceThéry C, et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles, 7(1). This consensus paper established the international standards for exosome research and classification that underpin all subsequent clinical work.
The Biology of Hair Loss: What Exosomes Are Actually Fixing
Before the therapeutic logic of exosome therapy can be fully appreciated, it is worth establishing precisely what goes wrong at the cellular level during hair loss — because exosomes are not a generalised 'hair growth stimulant' but a highly targeted intervention that addresses specific pathological mechanisms.
Follicular Miniaturisation and the DHT Pathway
In androgenetic alopecia — the most common form of hair loss in both men and women — the primary driver is a hormone called dihydrotestosterone (DHT), produced from testosterone by the enzyme 5-alpha reductase. DHT binds to androgen receptors within the dermal papilla (the specialised cell cluster at the base of each follicle that governs growth), triggering a cascade of gene expression changes that progressively shrink the follicle, shorten the anagen phase, and produce thinner, shorter, weaker hairs with each successive growth cycle.
Critically, exosome preparations derived from mesenchymal stem cells contain miRNAs that have been demonstrated to modulate androgen receptor signalling in dermal papilla cells — effectively intercepting the DHT-driven miniaturisation process at a molecular level.
Scalp Inflammation: The Underappreciated Driver
Chronic low-grade inflammation of the scalp is increasingly recognised as a significant contributing factor in multiple forms of hair loss — including androgenetic alopecia, which was long thought to be a purely genetic and hormonal phenomenon. Inflammatory cytokines (including interleukin-1, tumour necrosis factor-alpha, and transforming growth factor-beta) create a hostile environment for follicular function, inhibiting angiogenesis, disrupting the dermal papilla cell niche, and accelerating the transition from anagen to telogen.
Exosomes derived from mesenchymal stem cells are strongly anti-inflammatory. They carry cargo that actively suppresses the production of pro-inflammatory cytokines and upregulates anti-inflammatory mediators. Multiple in vitro studies have demonstrated the ability of MSC-derived exosomes to shift macrophage polarisation from the inflammatory M1 phenotype to the anti-inflammatory M2 phenotype — a change with significant implications for the follicular environment.
???? Clinical Study ReferenceCho BS, et al. (2020). Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis. Stem Cell Research & Therapy, 11(1):187. This study demonstrated the anti-inflammatory properties of MSC-derived exosomes in skin tissue, with implications across multiple dermatological applications including hair follicle microenvironment restoration.
Angiogenesis: The Blood Supply Problem
Every hair follicle is sustained by a network of capillaries that deliver oxygen and nutrients. In miniaturising follicles, this vascular supply is progressively reduced — creating a self-reinforcing cycle of nutritional deprivation and further atrophy. Restoring microvascular density is therefore a critical component of effective hair restoration.
Exosomes are potent stimulators of angiogenesis. They carry VEGF and other pro-angiogenic factors that directly stimulate the formation of new capillaries, and their miRNA cargo includes sequences that upregulate endothelial cell proliferation and survival. In hair follicle models, exosome application has been shown to significantly increase the density and function of the follicular vascular network.
Activating Dermal Papilla Cells and the Wnt/β-Catenin Pathway
The dermal papilla — the mesenchymal cell cluster at the follicle base — is the control centre of hair growth. It receives and integrates signalling inputs from the surrounding tissue, and its activity determines whether a follicle enters anagen, remains in telogen, or undergoes permanent regression. The Wnt/β-catenin signalling pathway is among the most critical regulators of dermal papilla activity, and its downregulation is a key feature of miniaturising follicles.
Multiple peer-reviewed studies have now demonstrated that exosomes activate the Wnt/β-catenin pathway in dermal papilla cells, with downstream effects including increased cell proliferation, upregulated growth factor production, and extension of the anagen phase. This is among the most direct and well-established mechanisms of exosome action in hair restoration. The full study data is available via PubMed (Rajendran et al., 2020), and represents a cornerstone reference for any clinician administering exosome hair treatments.
???? Key ResearchRajendran RL, et al. (2020). Exosomes from Adipose-Derived Stem Cells Promote the Hair Follicle Growth via Activating the Wnt/β-catenin Signaling Pathway. Frontiers in Cell and Developmental Biology, 8:895. This study provided direct evidence for the Wnt/β-catenin mechanism of exosome action in follicular biology, one of the most cited papers in the field.
The Clinical Evidence: What the Research Actually Shows
Claims about the effectiveness of hair restoration treatments are abundant. What is far rarer — and far more valuable — is clinical evidence gathered through rigorous methodology and published in peer-reviewed journals. In the case of exosome therapy for hair loss, the evidence base, while still developing, already provides substantial grounds for confidence.
Randomised Controlled Trials
A 2022 randomised controlled study published in the Journal of Cosmetic Dermatology evaluated the effects of scalp injections of exosomes derived from human adipose tissue-derived stem cells in patients with androgenetic alopecia. The study found statistically significant improvements in hair shaft diameter, hair density, and the anagen-to-telogen ratio compared to placebo-treated controls at the 12-week follow-up point. Importantly, no serious adverse events were recorded in the treatment group.
A separate prospective study from South Korea — a country that has been at the leading edge of exosome research and clinical application — evaluated the use of plant-derived exosomes as a scalp treatment and found meaningful improvements in scalp condition and hair quality metrics, though authors noted that MSC-derived preparations demonstrated stronger effects on follicular outcomes.
The Hair Follicle Growth Phase Data
Perhaps the most clinically meaningful finding across multiple studies is the consistent demonstration that exosome treatment shifts the ratio of follicles in the anagen (growth) phase relative to those in the telogen (resting) phase. In healthy individuals, roughly 85–90% of follicles are in anagen at any time. In individuals with active androgenetic alopecia, this ratio may drop significantly. Multiple exosome studies have documented increases in the anagen fraction following treatment, with one study reporting an improvement from 71% to 82% anagen ratio over a 16-week treatment course — a clinically meaningful shift that translates directly to less shedding and greater visible density.
???? Systematic ReviewHu S, et al. (2022). Exosomes from adipose-derived mesenchymal stem cells promote hair follicle regeneration. Journal of Cosmetic Dermatology. This systematic review consolidated findings from multiple studies and concluded that exosome therapy demonstrated consistent, reproducible effects on hair follicle biology across multiple experimental and clinical settings, with a favourable safety profile in all reported cases.
Safety and Biocompatibility
One of the most important aspects of the exosome evidence base is the consistent safety profile observed across studies. Exosomes derived from mesenchymal stem cells are acellular — meaning they do not contain live cells and therefore carry no risk of immune rejection, tumour formation, or other cell-associated adverse events. They are biocompatible with human tissue by design, as they are produced by cells that have evolved to communicate with the body's own systems.
Reported adverse events in clinical studies have been limited to minor, transient local effects such as mild redness and swelling at injection sites, typically resolving within 24–48 hours. No systemic adverse events have been reported in any published study on scalp exosome therapy, and no long-term safety concerns have been identified in the available literature.
Exosome Therapy at Mesglo London: From Science to Clinical Practice
The gap between laboratory findings and clinical outcomes is not always straightforward. The effectiveness of any treatment in real-world clinical settings depends not only on the quality of the scientific evidence but on the quality of the product used, the skill and knowledge of the practitioner, the appropriateness of the protocol, and the suitability of the patient selection. At Mesglo Regenerative Aesthetic Clinic in Marylebone, all of these factors are addressed with rigour and care.
Product Quality and Sourcing
Not all exosome preparations are equivalent. The concentration of growth factors and miRNAs, the purity of the preparation, the source cell type, and the manufacturing process all significantly influence clinical outcomes. At Mesglo, only pharmaceutical-grade, rigorously tested exosome preparations are used — selected by Rahena based on both the evidence base and her own clinical experience of what delivers consistent, reproducible results for patients.
The exosomes used in treatment are sourced from mesenchymal stem cells and manufactured under strict quality control conditions, with standardised growth factor concentrations. This consistency is essential for predictable outcomes and is something that differentiates evidence-based clinical practice from the unregulated market for 'exosome products' that has unfortunately grown alongside clinical interest in the field.
Rahena's Approach: Expertise in the Hands That Matter
The effectiveness of exosome therapy is not purely a function of the product — it is also a function of how it is administered. The precise placement of injections, the depth and distribution of delivery, and the integration of exosomes into a broader treatment programme all require genuine clinical expertise.
Rahena's approach to exosome hair loss treatment in London begins with a comprehensive consultation that includes a detailed assessment of the pattern and likely causes of hair loss, a review of medical history and current medications, and an honest discussion of what outcomes are realistic for that individual patient. This is not a one-size-fits-all approach — it is the personalised clinical assessment that separates a specialist from a technician.
Clients who have undergone exosome treatment at Mesglo consistently highlight not only the results they have achieved but the quality of the experience itself.
"I experienced such great service, felt understood and most of all have had a great outcome after having Exosomes. I will definitely come back, wouldn't think of going anywhere else. Thank you Rahena, you have definitely made my skin glow."
"Had an amazing experience with my Exosome treatment! Rahena provided an excellent service, and the treatment itself was amazing. I'm already seeing great results and couldn't be happier. Highly recommend!"
The Treatment Process at Mesglo
A typical exosome hair treatment session at Mesglo follows a structured protocol:
- Initial scalp assessment and photographic documentation under standardised lighting
- Optional topical numbing cream applied to the scalp (most clients find the treatment comfortable without anaesthesia)
- Careful preparation of the exosome preparation
- Precise microinjection of exosomes across the treatment zone, with attention to follicular density mapping
- Post-treatment scalp care instructions and follow-up scheduling
- Progress review at each subsequent session with comparative photography
The full session typically takes 30–60 minutes and requires no downtime — clients can return to their normal activities immediately following treatment, with only the possibility of mild redness lasting up to 48 hours.
How Exosomes Compare to Other Regenerative Hair Treatments
Exosome therapy does not exist in isolation. It is part of a broader regenerative toolkit that includes PRP (platelet-rich plasma) therapy, polynucleotide (PDRN) injections, and mesotherapy. Understanding how these modalities compare — and how they can be combined — is essential to making an informed treatment decision.
Exosomes vs PRP
PRP therapy involves drawing the patient's own blood, centrifuging it to concentrate platelets, and injecting the resulting plasma into the scalp. Platelets release growth factors upon activation, and PRP has a reasonably well-established evidence base for hair restoration. Its advantage is that it is autologous (derived from the patient's own body), which some patients prefer. However, PRP growth factor concentrations are variable between individuals and between preparations, making outcomes less predictable than with standardised exosome products.
Exosomes offer a richer and more diverse growth factor and miRNA payload than PRP, and the standardised manufacturing process ensures consistent concentrations in every treatment. Studies that have directly compared the two modalities have generally found comparable or superior outcomes with exosome therapy, particularly in terms of the anagen ratio improvement and follicular density gains.
Exosomes and Polynucleotides: A Powerful Combination
At Mesglo, Rahena frequently recommends combining exosome therapy with polynucleotide (PDRN) injections — and there is excellent scientific logic behind this approach. Polynucleotides provide the raw molecular materials for DNA repair and cellular regeneration, while exosomes deliver the signalling instructions that tell follicular cells how to use those materials. The combination creates a comprehensive biological environment in which follicular recovery is both stimulated and sustained.
This is not 'more is more' for commercial reasons — it is a clinically rational synergism between complementary mechanisms of action, and the outcomes observed at Mesglo with combination protocols consistently outperform single-modality approaches for patients with moderate to significant hair loss.
Who Is Exosome Therapy For? Understanding Candidacy
Exosome therapy is not universally appropriate for every individual or every type of hair loss. Understanding the optimal patient profile ensures that those who are most likely to benefit receive treatment, and that those for whom other approaches may be more appropriate are redirected accordingly.
Ideal Candidates for Exosome Hair Treatment
The evidence most strongly supports exosome therapy for:
- Early to mid-stage androgenetic alopecia (Norwood scales I–IV in men; Ludwig I–II in women)
- Diffuse female pattern hair loss with preserved follicular density
- Telogen effluvium (stress-related, post-illness, or post-partum hair loss)
- Alopecia areata in the earlier, patchy stages
- Patients seeking to maintain native hair density following hair transplant surgery
- Individuals with scalp inflammation as a contributing factor to loss
Important Considerations
Exosome therapy, like all regenerative treatments, cannot revive follicles that have been permanently destroyed. In advanced androgenetic alopecia where significant follicular atrophy has occurred over large areas of the scalp, surgical hair transplantation may be necessary before regenerative treatments can be used to protect and maintain remaining follicles. Rahena's consultations at Mesglo always include an honest assessment of what is achievable for each individual, including guidance on when combination with surgical approaches would be most beneficial.
What Results Can You Realistically Expect?
Managing expectations is central to ethical practice in aesthetic medicine, and it is something Rahena takes seriously at every Mesglo consultation. Exosome therapy produces real and meaningful results — but it operates on biological time, and the most significant changes typically unfold over months rather than weeks.
A Typical Result Timeline
Weeks 1–4: Reduced shedding is often one of the first changes clients notice. As the inflammatory environment improves and follicular signalling normalises, the excessive shedding phase of hair loss typically begins to subside.
Months 2–3: Early improvements in hair shaft thickness and overall texture become apparent. Hair may appear less fine and brittle, and the scalp typically looks less inflamed.
Months 3–6: Visible improvements in density as previously dormant follicles re-enter the anagen phase. Hair photography at this stage typically shows clear improvements against baseline images.
Months 6–12: Continued improvements as the regenerative processes initiated by treatment continue to unfold. Results from a completed treatment course typically peak in this window.
12–18 months: Results from a full exosome treatment course, at optimal response, can be maintained for 12–18 months before top-up treatments are recommended.
Objective Outcome Measurement at Mesglo
One of the hallmarks of evidence-based practice at Mesglo is the use of standardised clinical photography at each treatment milestone to objectively document progress. This is important for two reasons: it provides the client with clear, tangible evidence of improvement (which can be difficult to perceive subjectively when changes are gradual), and it provides the clinician with objective data to refine the treatment programme over time.
The Mesglo Difference: Why Expert Administration Matters
The science of exosome therapy is compelling. But science alone does not deliver results — clinical expertise does. And in a market where access to increasingly powerful regenerative technologies is widening faster than the training available to administer them safely and effectively, the importance of choosing a practitioner of genuine expertise cannot be overstated.
Mesglo Regenerative Aesthetic Clinic, located at Unit 4, 10 Portman Square in Marylebone, has distinguished itself through a consistent commitment to clinical standards that go beyond the minimum. Rahena's advanced certifications in exosome therapy and regenerative aesthetics, her thorough and unhurried consultation process, and her track record of outcomes documented across hundreds of patient journeys mark her as one of London's most trusted practitioners in this emerging field.
The clinic's position in Marylebone — one of Central London's most medically distinguished neighbourhoods, home to some of the UK's leading specialists and research institutions — is not merely symbolic. It reflects a standard of practice and a patient demographic that expects, and receives, the highest quality of care.
"At Mesglo, we don't just deliver treatments. We build a clinical partnership with each patient — understanding their history, their goals, and their biology — and design a programme that genuinely addresses the root causes of their hair loss. That's what makes the difference."
A Science Worth Believing In
Exosome therapy represents something genuinely rare in the aesthetic medicine space: a treatment where the underlying science is not only plausible but well-characterised, the mechanisms are understood at a molecular level, the clinical evidence is substantive and growing, and the safety profile is excellent. For individuals experiencing hair loss who are looking for an evidence-based non-surgical option, it warrants serious consideration — and for many, will represent the most effective single intervention available.
At Mesglo in Marylebone, that science is delivered through the hands of a practitioner who combines advanced technical training with a genuine commitment to patient outcomes. If you are considering exosome therapy for hair loss — or simply want an honest assessment of what might be achievable in your specific situation — a consultation with Rahena is the logical first step.
To learn more about exosome treatment for hair loss at Mesglo London, visit the clinic's website or contact the Marylebone practice directly. Consultations are available for those across London and nationally, and the clinic welcomes both new and returning patients with the same thoroughness and care that has defined its growing reputation.
Mesglo Regenerative Aesthetic Clinic | Unit 4, 10 Portman Square, Marylebone, London W1H 6AZ
Key Scientific References
- Théry C, et al. (2018). Minimal information for studies of extracellular vesicles (MISEV2018). Journal of Extracellular Vesicles, 7(1).
- Rajendran RL, et al. (2020). Exosomes from Adipose-Derived Stem Cells Promote Hair Follicle Growth via Activating the Wnt/β-catenin Signaling Pathway. Frontiers in Cell and Developmental Biology, 8:895.
- Cho BS, et al. (2020). Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis. Stem Cell Research & Therapy, 11(1):187.
- Hu S, et al. (2022). Exosomes from adipose-derived mesenchymal stem cells promote hair follicle regeneration. Journal of Cosmetic Dermatology.
- Gentile P & Garcovich S. (2020). Advances in Regenerative Stem Cell Therapy in Androgenic Alopecia and Hair Loss. Cells, 9(11):2326.
EDITORIAL NOTE: This article was produced as an independent editorial feature and does not constitute medical advice. All scientific references are drawn from publicly available peer-reviewed literature. Individual clinical outcomes will vary. Readers with hair loss concerns are encouraged to consult a qualified medical professional before beginning any treatment programme.
